Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis

Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis

To determine the efficacy and safety S-adenosyl-l-methionine in alcoholic hepatitis with cholestasis.

randomize first time for core treatment stage for 6 weeks, then randomized second time for extend treatment for 42 weeks.

Inclusion Criteria:

• Body Mass Index range 19-30kg/m2
• Alcohol Drinking history more than 5 years, for male ≥ 40g/ day, for female ≥ 20g/ day;
• STB from 2 to 10X ULN;
• ALP>1.5X ULN or GGT>3X ULN

Exclusion Criteria: any one of below,

• active virus hepatitis, or anti-HIV(+)
• exclude other hepatic disease: non-alcoholic fatty liver, drug-induced liver injury, autoimmune hepatitis( AMA/ANA>1:100), Wilson disease, hemochromatosis or other hepatic disease; obstructive cholestasis
• other non-hepatic diseases caused jaundice
• primary hepatic carcinoma